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1Introduction
Survivors of allogeneic Blood and Marrow Transplant 
(BMT) are at a significant risk of developing many long- 
term and adverse late effects in the years following 
transplantation [1]. Of these late effects, secondary malig-
nancies are a particular concern. Cumulative incidence 
rates of up to 12% at 15 years post- BMT have been 
reported, and no plateau has been identified [2, 3]. All 
cancers have been found to occur in survivors of BMT 
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Abstract
Allogeneic Blood and Marrow Transplant (BMT) survivors are at high risk of 
secondary cancers. Although current guidelines endorse survivors following 
Country- specific general population screening recommendations to mitigate this 
risk, little is known about cancer screening adherence in Australian BMT sur-
vivors. We conducted a cross- sectional survey of 441 BMT survivors who were 
>1 year post transplant, to explore rates of screening for secondary cancers and 
to identify barriers to cancer screening recommendations. Survey instruments 
included the Sydney Post- BMT Survey, FACT- BMT, DASS 21, The Chronic 
Graft versus Host Disease (GVHD) Activity Assessment–Patient Self- Report (Form 
B), the Lee Chronic GVHD Symptom Scale, Fear of Cancer Recurrence Scale, 
and The Post Traumatic Growth Inventory. Fifty- seven percent of respondents 
were male, median age 54 years, and 40% were >6 years post- BMT. Rates of 
cancer screening adherence were as follows: cervical 63.4%, breast 53.3%, skin 
52.4%, and bowel 32.3%. Older BMT survivors and those >2 years post trans-
plant were more likely to undergo cancer screening. Improved quality of life 
was associated with screening for skin, breast, and cervical cancer. Fear of cancer 
recurrence negatively impacted on cervical screening. For those who had not 
undergone screening, the majority reported not being advised to do so by their 
treatment team. This study is the largest and most comprehensive to date ex-
ploring cancer screening adherence in BMT survivors in Australia. These data 
provide the basis for health service reform to better meet the needs of BMT 
survivors and provide evidence to support counseling and education of both 
patients and professionals.
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with skin, thyroid, oral cavity, esophagus, breast, liver, 
brain/nervous system, bone, and connective tissue cancers, 
all more frequently diagnosed in BMT survivors than the 
general population [4–6]. Risk factors for higher rates of 
secondary cancers include younger age at BMT, total body 
irradiation (TBI), prolonged immunosuppression, chronic 
graft- versus- host disease (cGVHD), and smoking prior to 
allogeneic BMT [5–8].
For almost a decade international consensus guidelines 
for the care of long- term survivors of BMT have been 
available [9, 10]. These guidelines include recommenda-
tions for cancer screening, preventive health care and 
health promotion, noting that survivors follow general 
population screening recommendations in their country 
for breast, cervical, skin, genital, and bowel cancer, and 
avoid high- risk behaviors (smoking, excess drinking, over-
weight and obesity, inactivity, and unprotected skin UV 
exposure). These guidelines also make clear that in patients 
with chronic GVHD, additional attention needs to be paid 
to surveillance for oral, pharyngeal, and early skin cancer. 
While some controversy exists regarding the commence-
ment, frequency, and modality for breast cancer screening, 
it is generally suggested that for woman who received 
TBI and/or chest irradiation, mammography screening 
should be commenced at age 25 or 8 years after radiation 
exposure, whichever occurs later, but no later than age 
40 years [8, 10, 11].
In Australia, the Commonwealth Government funds 
three national screening programs to reduce the burden 
of cancer nationwide; Breast Screen Australia, the National 
Cervical Screening Program, and the National Bowel Cancer 
Screening Program. These programs offer free screening 
to the Australian public at specific age and interval time 
points (Table 1) [12, 13]. Cancer Australia (the lead 
national cancer control agency) also advocates known 
healthy lifestyle behaviors such as quitting smoking, being 
‘sun smart’, being active, maintaining a healthy diet, and 
limiting alcohol intake for the entire population. 
Participation in these programs and health promotion 
behaviors in Australian BMT survivors is largely unknown.
Despite the availability of long- term follow- up guidelines 
[9, 10], and the excess burden of secondary cancers post 
allogeneic BMT [14], international studies have shown 
that cancer screening uptake and health behaviors in BMT 
survivors are similar, if not worse than people who have 
had cancer but not had an allogeneic BMT, and people 
who have never had cancer [15, 16]. In this study we 
aimed to explore rates of screening for secondary malig-
nancies in an Australian cohort of allogeneic BMT survivors 
and identify barriers to adherence with cancer screening 
recommendations.
Methods
A cross- sectional survey of BMT survivors was undertaken 
to explore late effects of BMT and the quality of survival 
post transplant. This survey of BMT survivors in New 
South Wales (NSW) Australia included questions regard-
ing rates of secondary cancers, adherence to cancer 
screening, and modifiable healthy lifestyle behavior, 
together with demographic and social characteristic asso-
ciated with barriers to uptake of cancer screening 
recommendations.
NSW is Australia’s most populous state with a popula-
tion of ~7.5 million and covers an area of 800,628 km2. 
Over a third of residents live outside the greater Sydney 
area [17]. At the time of study commencement there 
were four adult allogeneic transplant centers in NSW, all 
Table 1. Australia’s National Cancer Screening Programs with recommendations for the general population [13].
Cancer Screening Program [13] Recommendations [13]
BreastScreen Australia BreastScreen Australia invites women aged 50–74 to have free 2 yearly mammogram. Women 
aged 40–49 and 75 and over are eligible to receive free mammograms, but do not receive an 
invitation to attend.
National Bowel Cancer Screening Program 
(NBCSP)
The NBCSP invites men and women turning 50, 55, 60, 64, 65, 70, 72, and 74 to screen for 
bowel cancer.
Participants are sent a free, easy to use screening kit that can be completed at home. 
Between 2015 and 2020, more age groups will be added to the screening program:
• 2017—68, 58, and 54 year olds.
• 2018—62 and 66 year olds.
• 2019 and 2020—52 and 56 year olds.
National Cervical Screening Program (NCSP) The NCSP invites all women aged between 18 and 70 who have ever been sexually active to have 
2 yearly Pap tests.
Cervical screening is provided through general practice, community or women’s health centers, 
family planning clinics, sexual health clinics, or Aboriginal Medical Services.
From 1 May 2017, the NCSP will be changed to inviting women aged 25–74 years (both HPV 
vaccinated and unvaccinated) to undertake an HPV test every 5 years.
3© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
Cancer Screening Adherence in Australian BMT SurvivorsG. Dyer et al.
based in Sydney and collectively performing approximately 
175 BMTs annually [18].
Potential participants were identified from allogeneic 
transplant databases from all adult allogeneic transplant 
centers in NSW. Participants were eligible if they were 
>18 years of age and had undergone an allogeneic BMT 
between 1 January 2000 and 31 December 2012, could 
read and write English, and could provide consent. Names 
and phone numbers were provided to the research team. 
Consenting participants were given the option to self- 
complete the questionnaire or complete it via a phone 
interview with one of the researchers. A second round 
of telephone calls was made to 187 participants who had 
not returned the survey within a month. All authors had 
access to primary clinical trial data. The study protocol 
was approved by the Northern Sydney Local Health District 
Human Research Ethics Committee (NSLHD Reference: 
1207- 217M).
Instruments
Participants were asked to complete seven instruments.
The Sydney Post BMT Study Survey (SPBS) was devel-
oped by the research team from a review of the literature 
and discussion with patients attending BMT long- term 
follow- up clinics. The survey comprised 402 questions 
grouped into 20 domains and included questions relating 
to secondary cancer diagnosis, cancer screening adherence, 
and lifestyle behavior choices. Other relevant domains 
included demographics, medical complications, tests and 
assessments, medications and therapies, infections, vac-
cinations, complementary therapy use, relationship status, 
income (Australian Dollars, AUD), and lifestyle factors, 
following allogeneic BMT. The questionnaire used tick 
box responses, short answer questions, and five- step Likert 
scales measuring attitudes and other factors and took 
approximately 1 h to complete. The questionnaire was 
piloted with six BMT survivors in clinic and phone inter-
views to assess face and content validity and to check 
for comprehension. For each consenting participant, data 
were collected on dates of diagnosis and transplant, stage/
remission status at transplant, transplant conditioning, 
GVHD prophylaxis, stem cell source, and donor type.
Cancer screening adherence and health behavior choices 
were analyzed according to a range of demographic, trans-
plant, psychosocial, and lifestyle variables assessed using 
the Functional Assessment of Cancer Therapy – Bone Marrow 
Transplant (FACT-BMT Version 4) [19, 20], anxiety stress 
and depression (The DASS 21) [21–23], chronic GVHD 
(The Chronic GVHD Activity Assessment – Patient Self 
Report (Form B) [24], The Lee Chronic GVHD Symptom 
Scale) [25], the Fear of Cancer Recurrence (FoCR) Scale 
[26], and The Post Traumatic Growth Inventory (PTGI) 
score [27, 28]. For ease of completion all instruments 
were combined into one booklet.
Statistical analysis
Categorical responses were summarized using frequencies 
and percentages. Parametric continuous variables were 
summarized using means and standard deviations, and 
nonparametric variables using medians, interquartile ranges 
(IQR), or ranges. Odds ratios and 95% confidence limits, 
Pearson χ2 test, or Fishers Exact tests were used for com-
parative analysis of dichotomous categorical variables and 
multivariable logistic regression to adjust for relevant 
confounders. Two sample comparisons of parametric and 
nonparametric data were determined using the independ-
ent t- test, and Wilcoxon rank sum tests, respectively; 
greater than two- sample comparisons were determined 
using one- way Analysis of Variance (ANOVA) and Kruskal–
Wallis tests, respectively. A two- tailed P- value <0.05 was 
used as the level of statistical significance.
Statistical analysis was performed using STATA version 
12.1 statistical package (StataCorp, College Station, TX).
Results
A total of 1475 Allogeneic BMT were performed in the 
study period. Of the 669 recipients known to be alive at 
study sampling, 583 were contactable and were sent study 
packs. Four hundred and forty one (66% of total eligible, 
76% of those contacted) returned the completed survey. 
Three percent (17) declined participation.
Of those completing the survey, 250 (57%) were male 
and 191 (43%) female. The median age of survey respond-
ents was 54 years (Range: 19–79). The median age at 
time of transplant was 49 years (Range: 17–71) (Table 2).
Secondary cancer diagnosis
One hundred and six (24.0%) reported a diagnosis of at 
least one cancer following BMT of which 104 were non-
relapse malignancies. Skin cancers accounted for the largest 
number of secondary cancers (Table 3).
Cancer screening
Skin cancer screening
A total of 436 (98.9%) participants provided a response 
to whether or not they had had undergone skin cancer 
screening since transplant. Two hundred and twenty eight 
(52.3%) reported having had a skin check and 208 (47.7%) 
reported never having had a skin check since BMT. Of 
those who reported having had a skin check, 75% had 
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done so in the preceding 18 months (range 1 month to 
9 years). One hundred and sixty six of the 228 (72.8%) 
reported attending for skin checks at least once a year.
Demographic, social, transplant- related, treatment- 
related, and behavioral factors were assessed for their 
association with having skin checks as part of cancer 
screening post transplant. Of note, skin checks were not 
significantly associated with skin GVHD, receipt of azole 
antifungals, or outdoor occupations (gardening, construc-
tion, or agriculture). Univariate analysis demonstrated a 
significantly increased odds of skin checks with older age, 
higher education status, being in a married or defacto 
relationship, and a high compliance with “sun smart” 
behaviors including the routine use of sunscreen, hats, 
sun protective attire, sunglasses, and sun avoidance during 
the daily periods for peak exposure. Factors associated 
with a reduced odds of skin checks on univariate analysis 
included an acute leukemia diagnosis, receipt of a myeloa-
blative conditioning regimen, and being within 2 years 
of transplant. After adjusting for potential confounders, 
those factors that demonstrated an independent and sig-
nificant association with having skin checks post transplant 
included older age (Adjusted 1.03 95% CI: 1.0, 1.05; 
P = 0.03), higher educational status (Adjusted Odds Ratio 
Table 2. Participant characteristics.
Sociodemographic
Gender (n = 441)
Male n (%) 250 (56.7%)
Female n (%) 191 (43.3%)
Age (years) at survey (n = 441)
Median (IQR; range) 54 (44,62; 19–79)
Age (years) at transplant (n = 441)
Median (IQR; range) 49 (38, 56; 17–71)
Ethnicity (n = 372)
Caucasian, European n (%) 323 (86.8%)
Other n (%) 49 (13.2%
Educational status (n = 333)
University (some/completed) n (%) 154 (46.2%)
Other1 n (%) 179 (53.8%)
Post transplant income status (AUD4) (n = 423)
Low income $20,000–$39,999 n (%) 155 (36.6%)
Middle income $40,000–$79,999 n (%) 123(29.1%)
High income ≥ $80,000 n (%) 145 (34.3%)
Residence (n = 431)
Major city n (%) 311 (72.2%)
Other (inner regional, outer regional, remote) n 
(%)
120 (27.8%)
Relationship status (n = 434)
Married–Defacto n (%) 344 (79.3%)
Other (separated, single, divorced) n (%) 90 (21.8%)
Transplant –related
Years since transplant (n = 441)
<2 years n (%) 58 (13.1%)
=2 to <6 years n (%) 204 (46.3%)
=6 to <10 years n (%) 117 (26.5%)
≥10 years n (%) 62(14.1%)
Underlying diagnosis (n = 423)
Acute leukemia (AML/ALL) n (%) 226 (53.4%)
Other2 n (%) 197 (46.6%)
Remission status (n = 405)
First/second complete remission 271 (66.9%)
Other3 134 (33.1%)
Donor type (n = 441)
Sibling n (%) 250 (59.9%)
Matched unrelated n (%) 158 (36.0%)
Haploidentical n (%) 10 (2.3%)
Mismatched unrelated n (%) 21 (4.8%)
Stem cell source(n = 441)
Bone marrow n (%) 48 (10.9%)
Peripheral blood n (%) 381 (86.4%)
Cord blood n (%) 12 (2.7%)
Conditioning chemotherapy (n = 439)
Myeloablative 214 (48.7%)
Reduced intensity 225 (51.3%)
1Other Education—secondary school (some or complete); trade or 
diploma.
2Other diagnoses: CML, Chronic Myeloid Leukemia; CLL, Chronic 
Lymphocytic Leukemia; NHL, Non- Hodgkin Lymphoma; HL, Hodgkin 
Lymphoma; MM, Multiple Myeloma; Myelodysplastic Syndrome/
Myeloproliferative disorder; Other (unspecified).
3Other remission status; more than second complete remission; 
Refractory; Chronic Phase; Accelerated Phase; Blast Crisis; Partial 
Remission; other (unspecified).
4AUD—Australian Dollars; IRQ, interquartile ranges.
Table 3. Secondary cancer diagnosis post blood and marrow transplant 
(BMT).
Cancer types (N = Number of 
Responses)
n (% reporting cancer 
type of total responses)
Skin cancer (n = 404) 93(23.0%)
Skin cancer type % of all skin cancers
Basal cell carcinoma (BCC) 41 (44%)
Squamous cell carcinoma (SCC) 14 (15%)
Melanoma 5 (6%)
Mixed 17 (18%)
BCC + SCC 14(15%)
BCC + Melanoma 2 (2%)
SCC + Melanoma 1(1%)
Unspecified/don’t know 16(17%)
Mouth cancers (n = 392) 6 (1.5%)
Other (n = 370) 18 (4.9%) 
n (% of all other cancers)
Urological (prostate and/or bladder) 5/18 (27%)1
Breast 2(11%)
Bowel 1(6%)
Ovarian 1(6%)
Myeloid sarcoma 1(6%)
Head (unspecified) 1(6%)
Hematological (nonrelapse) 5 (27%)2
Hematological (relapse) 2(11%)3
13 prostate, 1 bladder, 1 bladder + prostate.
21 NHL (primary = AML); 1 NHL (Primary = SAA); 2 Hodgkin Lymphoma 
(Primary = NHL); 1 post transplant lymphoproliferative disease.
31 Relapse AML; 1 relapse Mantle Cell Lymphoma; AUD, Australian 
Dollars
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[AOR]: 1.87 95% CI: 1.11, 3.15; P = 0.02), and “Sun 
smart” behavior (AOR: 1.89 95% CI: 1.06, 3.37; P = 0.03).
Compliance with skin cancer screening was further 
assessed against measures including quality of life (FACT- 
BMT and subscales) and psychological morbidity (DASS21 
and subscales), Lee GVHD scores, self- reported GVHD 
symptom severity, and Fear of Cancer recurrence and 
Post Transplant Growth Inventory scores. Survivors who 
had skin checks had significantly higher scores on FACT 
emotional subscale (P = 0.03), BMT subscale (P = 0.007), 
and overall FACT- BMT scores (P = 0.03), and significantly 
lower scores on depression subscales (P = 0.02), with no 
significant difference observed on other subscale or com-
posite DASS21 measures (Appendix A1).
Reasons cited for not undergoing skin cancer screening 
in 208 patients included lack of time in 13 (6.2%), cost 
in five (2.5%), and belief that screening was not necessary 
in 54 (26.0%). One hundred and forty nine patients 
(71.6%) indicated that they had not been advised by their 
treating team to undergo skin cancer screening. Twenty 
nine (13.9%) of those who had never undertaken skin 
cancer screening were receiving azole antifungal 
therapy.
Bowel cancer screening
A total of 432 participants provided a response to whether 
or not they had undergone bowel cancer screening (either 
colonoscopy or stool hemoccult testing) since transplant. 
One hundred and forty (32.4%) reported having had a 
bowel cancer check and 292 (67.6%) reported not having 
had a bowel cancer check since BMT. Of those who 
reported having had a bowel cancer check, 75% had done 
so in the preceding 2 years (range <1 month to 11 years). 
Forty- seven of 140 (33.8%) reported having bowel checks 
at least every 2 years.
On univariate analysis, older BMT survivors and those 
in a married or defacto relationship showed a significantly 
increased odds of undergoing bowel cancer screening. 
Transplant- related factors including an underlying diag-
nosis of acute leukemia and receiving myeloablative con-
ditioning were associated with significantly decreased odds 
of bowel cancer screening. On multivariable analysis, the 
only variable with an independent and significant increased 
association with bowel cancer screening was older age 
(AOR: 1.06; 95% CI: 1.03, 1.08; P < 0.0001).
No significant differences were evident in DASS21 and 
FACT- BMT scores and subscales, Lee GVHD or other 
psychosocial metrics in those who reported bowel screen-
ing and those who did not (Appendix A2).
Of the 292 patients who did not have bowel screening, 
8 (2.7%) cited time, 2 (0.7%) cost, and 75 (25.7%) feel-
ing that screening was not necessary as the main reasons 
for not attending to a bowel check since transplant. Two 
hundred and twenty five patients (77% of those not hav-
ing a bowel cancer check) reported that they had not 
been advised to undergo bowel cancer screening by their 
treating team.
Cervical cancer screening
A total of 186 of female participants provided a response 
to whether or not they had had a Paapaniolou (pap) 
smear since transplant. One hundred and eighteen (63.4%) 
females reported having had a pap smear and sixty eight 
(36.6%) reported not having had a pap smear since BMT. 
Of those who reported having had a pap smear, 75% 
had done so in the preceding 2 years (range: 1 month 
to 5 years).
Younger age was significantly associated with having 
had a pap smear (P = 0.04) and women who were less 
likely to have had a pap smear if within 2 years of the 
transplant procedure. Following multivariable analysis, a 
trend for a reduced odds with older age was observed 
(AOR: 0.97; 95% CI: 0.94, 1.0: P = 0.09) and a signifi-
cantly reduced odds of pap screening for women less 
than 2 years post transplant (AOR: 0.30; 95% CI: 0.11, 
0.85: P = 0.02).
Those reporting cervical cancer screening post transplant 
showed no overall differences in DASS 21 scores, although 
on a trend toward lower Anxiety scores was observed in 
females who had undergone pap screening (P = 0.06). 
Patients undergoing pap screening reported a trend toward 
higher emotional subscale scores (P = 0.054) and signifi-
cantly higher functional well- being (P = 0.008) and overall 
scores on FACT- BMT (P = 0.02). This would suggest a 
positive association between improved quality of life in 
women who had pap screening. Lower uptake of cervical 
screening was associated with a significantly increased fear 
of cancer recurrence (FoCR) score (P = 0.003). 
(Appendix A3).
Barriers to undergoing cervical cancer screening included 
lack of time in 8 (11.8%), cost in 2 (2.9%), and a belief 
that Pap screening was not necessary in 20 (29.4%). A 
total of 31 women (45.6%) reported that they had not 
been advised to have a Pap smear by their treating team.
Breast cancer screening
A total of 184 female participants provided a response 
to whether or not they had had a mammogram for breast 
cancer screening since transplant. Ninety- eight (53.3%) 
females reported having had a mammogram and 86 (46.7%) 
reported not having had a mammogram since BMT. 
Seventy- five percent reporting having a mammogram in 
the preceding 2 years (range 2.5 month to 4 years). The 
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age of first mammogram was reported by 68 women; in 
their 20s (8), 30s (12), 40s (31), 50s (16), and 60s (1). 
Older age (AOR: 1.11; 95% CI: 1.07, 1.16; P < 0.001) 
and residing in a city/inner- regional center (AOR: 5.33; 
95% CI: 1.37, 20.8; P = 0.03) were the only variables 
associated with a significantly increased odds of screening 
mammography on multivariable analysis. Total Body 
Irradiation (TBI) as part of the conditioning regimen 
showed a trend toward increased mammography uptake 
(AOR: 2.35; 95% CI: 0.99, 5.58; P = 0.052) and being 
less than 2 years post transplant a trend toward decreased 
mammography uptake (AOR: 0.31; 95% CI: 0.09, 1.05; 
P = 0.06).
For those reporting mammography screening post trans-
plant, there were no overall differences in DASS 21 scores, 
although lower depression subscales were associated with 
mammography uptake (P = 0.04). Patients undergoing 
mammography reported significantly higher emotional 
(P < 0.001) and BMT subscale scores on FACT- BMT 
(P = 0.02). This would suggest a positive association 
between improved quality of life in women who had 
mammography. Mammography screening was associated 
with significantly lower median Lee GVHD severity scores 
(P = 0.02), although no significant differences were observed 
using the alternative metric for GVHD severity (cGVHD 
activity assessment Form B) (Appendix A4).
For those not having mammography, 5 (5.8%) reported 
lack of time, 2 (2.3%) had an issue with cost, 23 (26.7%) 
felt it was not necessary, and 57 (66.3%) reported not 
being advised by their treating team to undergo breast 
cancer screening.
Discussion
The results of this study confirm that secondary cancers 
occur commonly after allogeneic transplantation [7, 29, 
30] and that cancer screening is not being performed 
according to recommended BMT long- term follow- up 
guidelines [10, 15] or with recommendations for cancer 
screening in the general Australian population [12]. Our 
cohort had lower rates of screening for bowel cancer 
(32.3%), cervical cancer (63.4%), and breast cancer (53.3%) 
than previous studies in BMT survivor populations [31]. 
These rates are, however, similar to adherence rates among 
the general Australian population who participate in Breast 
Screen Australia (55%), the National Cervical Screening 
Program (58%), and the National Bowel Cancer Screening 
Program (33%) [12]. Only half of the cohort had had a 
skin cancer check (52.4%) following transplant. This is 
significant because although there is currently insufficient 
evidence to support population- based screening for non-
melanocytic and melanoma skin cancer [32], and skin 
cancer screening not recommended by major public health 
bodies [12, 32], Australians experience a melanoma inci-
dence rate 11 times that of the average world rate [12] 
and BMT recipients are at markedly higher risk of devel-
oping all forms of skin cancer as a consequence of cuta-
neous graft- versus- host disease (GVHD), long- term use 
of immunosuppressive drugs, and azole antifungal agents 
[29].
In this study the major determinant of cancer screen-
ing, with the exception of cervical screening, was older 
age. In contrast to other studies, which have shown that 
being further out from BMT decreased adherence to pre-
ventive care practices [31], we observed a trend toward 
increased screening for skin, bowel, and breast cancers 
in late compared to early transplant survivors. A signifi-
cant association with cervical screening was observed in 
females beyond the first 2 years of their transplant pro-
cedure. It is difficult, however, to know the significance 
of this finding as there are no data regarding whether 
the age time points for general population cancer screen-
ing apply to BMT survivors, many of whom experience 
an increased risk from a younger age of secondary cancer, 
particularly breast and skin cancers. For this reason alone 
the ‘benchmarking’ of cancer screening adherence against 
general population recommendations raise real questions 
regarding best practice and the possibility of both over- 
and underdiagnosis [33]. In this regard it is noteworthy 
that rates of cancer screening in our study population 
were not only inconsistent with recommendations for 
general population screening but also with recommenda-
tions for BMT recipients and for high- risk cancer survivors. 
The finding that women exposed to TBI were no more 
likely to have mammography or to commence mammog-
raphy at an earlier age is of enormous concern given 
the recognized association between radiation exposure and 
breast cancer [34].
Interestingly, our study found a significant association 
between participation in skin, cervical, and breast cancer 
screening and higher quality of life. Although this is reas-
suring to those involved in post transplant care, it runs 
counter to recent literature that suggests that cancer screen-
ing can increase anxiety and overdiagnosis [33, 35]. There 
are at least two possible explanations for this finding—
firstly, that those who report higher quality of life may 
be more motivated to maintain good health, or conversely, 
participating in cancer prevention may confer quality of 
life and survival benefits.
We were unable to identify a significant association 
between social factors such as being in a married/defacto 
relationship with increased screening uptake, a finding 
that is otherwise well- described in other cancer screening 
studies [36–39].
Fear of cancer recurrence (FoCR) in those with an 
underlying hematological malignancy at transplantation 
7© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
Cancer Screening Adherence in Australian BMT SurvivorsG. Dyer et al.
was investigated for its associations with screening uptake. 
FoCR was negatively associated with cervical screening 
uptake, but had no association with other screening pro-
cedures. Positive measures of personal growth assessed 
using the PGTI was not associated with adherence to 
cancer screening. The severity of GVHD symptoms was 
further explored for any potential association with screen-
ing uptake. We hypothesized that more symptomatic 
GVHD may result in patients being under closer medical 
surveillance and, therefore, more likely to be screened for 
cancers. Lee GVHD scores were observed to in fact be 
lower in females who did undergo post transplant breast 
screening, which may also attest to the better quality of 
life that such patients have.
Perhaps most importantly, the results of our study 
provide clues as why BMT survivors may not participate 
in cancer screening programs. Over a quarter of our 
respondents reported that they did not feel that screening 
was necessary—suggesting failures in the education and/
or counseling of transplant recipients—a finding reported 
in previous studies [14]. In addition, of those who reported 
that they had not undergone any cancer screening, the 
vast majority gave the reason that the screening test/s 
had not been recommended by their treating team. While 
we did not verify this report for individual patients, it 
is consistent with the findings of studies conducted in 
general populations [40] and may likely be true in this 
population given the inadequate resourcing of post trans-
plant care in many BMT centers. Cost was reported to 
be a barrier to uptake for very few survivors in our study; 
however, financial difficulties (low income) have been 
shown to impact cancer screening rates in other popula-
tions [38]. This may be a function of Australia’s afore-
mentioned free national cancer screening programs. The 
barrier of cost was reported for younger survivors who 
do not meet age criteria (e.g., annual mammograms for 
those age 25 years if they had TBI). These explanations 
for the low rates of adherence with cancer screening rec-
ommendations are also consistent with the literature that 
suggests that many factors may act as barriers to optimal 
preventive care including: lack of knowledge regarding 
the importance of cancer screening in both patients and 
providers, deficiencies in the organization of preventive 
health- care services [31], and skepticism regarding the 
value of screening [33, 41].
This study is important because it is one of the largest 
studies describing adherence with cancer screening guide-
lines in a BMT population and the first to explore cancer 
risk behavior and adherence to cancer screening guidelines 
in an Australian cohort of BMT survivors. Although the 
sample size and high response rate (76%) make it likely 
that these results represent an accurate account of BMT 
survivor’s health behaviors, there are a number of 
limitations to our study which may limit the generalizability 
of these results to BMT survivors in other countries and 
other settings. These limitations are principally a function 
of our study population and include Australia’s geographi-
cal size, population pattern, climate and health system 
(which includes both universal publicly funded and private 
health care), and funded national cancer screening pro-
grams. The fact that the study relied upon self- reporting 
and did not capture data on nonresponders also limits 
our findings. Another area which may have been of inter-
est is that relating to digital rectal examination (DRE) 
and/or prostate- specific antigen (PSA) for prostate cancer 
screening in BMT survivors, however, due to the con-
troversy regarding these modalities [42–45], and that 
general population prostate cancer screening is not rec-
ommended in Australia, we did not ask participants about 
this. Additionally, it should be noted that as only two of 
the respondents had a recurrence of the malignancy for 
which they were transplanted, our findings only apply to 
survivors who remain disease free following BMT. Also, 
as we did not ask respondents about adherence to cancer 
screening guidelines pre- BMT, we are not able to make 
any correlation between pre- and post- BMT practices.
What this study makes clear is that recommendations 
for cancer screening and for preventive health- care post- 
BMT are, in many situations, not being followed by 
health- care services and/or adopted by the target popula-
tion. Although the exact reasons for this require further 
qualitative study, it seems likely that this is a result of 
both systems failures and inadequate or unsuccessful patient 
education. It is also possible, but entirely speculative, that 
this may result from awareness that there is currently 
limited data to support cancer screening in BMT patients—
including those most at risk. Absence of good quality 
long- term data does not, however, create an argument 
for therapeutic nihilism or for failures to deliver com-
prehensive care post- BMT. Rather, data from studies such 
as this one should be used to drive the development and 
implementation of models of chronic care post- BMT that 
address gaps in health promotion, behavior modification, 
and cancer screening in order to prevent morbidity and 
mortality in long- term BMT survivors and increase aware-
ness in health professionals and patients alike of the 
increased risk of secondary cancers in survivors of BMT.
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Appendix A1. Demographic, social determinants, transplant factors, and instrument measures (QoL, psychological morbidity, GVHD, FoCR, PTGI), 
and their associations with having skin cancer screening.
Skin check 
N = 228
No skin check 
N = 208
OR (95% CI) Adjusted OR(95% CI)1 
P- value
Gender
Male 127/228 (55.7%) 121/208 (58.2%) 0.90 (0.61, 1.34)
Female 101/228 (44.3%) 87/208 (41.8%) 0.61
Age (median, IQR) 58 (48, 64) 51 (42, 59) 1.03 (1.02, 1.05) 1.03 (1.0, 1.05)
<0.0001 P = 0.03
Residence
City/inner regional 209/223 (93.7%) 182/203 (89.7%) 1.72 (0.81, 3.77)
Outer regional/remote 14/223 (6.3%) 21/203 (10.3%) 0.13
Education
Some/completed university 91/173 (52.6%) 60/156 (38.5%) 1.77 (1.12, 2.82) 1.87 (1.11, 3.15)
Trade/some or complete secondary school 82/173 (47.4%) 96/156 (61.5%) 0.03 P = 0.02
Household income (AUD)
Low income $20,000–$39,999 71 (32.7%) 83 (41.3%) 0.69 (0.45, 1.05) 0.73 (0.42, 1.27)
Middle/high income ≥ $40,000 146 (67.3%) 118 (58.7%) 0.07 P = 0.27
Marital status
Married/Defacto 188/225 (83.6%) 152/205 (74.1%) 1.77 (1.08, 2.92) 0.80(0.42, 1.51)
Single/divorced/separated 37/225 (17.3%) 53/205 (25.8%) 0.02 P = 0.48
Occupation
Gardener 11/210 (5.2%) 1/187 (0.5%)
Building/construction 17/211 (8.1%) 13/189 (6.9%)
Agriculture/Farm worker 9/209 (4.3%) 7/189 (3.7%) 1.44 (0.77, 2.79)
0.22
Any outdoor occupation
Yes (Gardener, Builder, Ag worker) 31/215 (14.4%) 20/192 (10.4%)
No 184/215 (85.6%) 172/192 (89.6%)
Years since transplant
<2 years 20/228 (8.8%) 37/208 (17.8%) 0.44 (0.23, 0.82) 0.69 (0.32, 1.48)
≥2 years 208/228 (91.2%) 171/208 (82.2%) 0.005 P = 0.34
Underlying diagnosis 100/215 (46.5%) 123/203 (60.6%) 0.56 (0.38, 0.85)
Acute leukemia 115/215 (53.5%) 80/123 (39.4%) 0.004 0.70 (0.42, 1.16)
Other P = 0.17
Donor type
Matched (sibling/unrelated) 213/226 (94.2%) 190/208 (91.3%) 1.55 (0.70, 3.54)
Mismatched (haploidentical, unrelated) 13/226 (5.8%) 18/208 (8.7%) 0.24
Conditioning
Myeloablative 98/226 (43.4%) 115/208 (55.3%) 0.62 (0.42, 0.92) 0.85 (0.49, 1.48)
Reduced Intensity 128/226 (56.6%) 93/208 (44.7%) 0.01 P = 0.57
Self- reported skin GVHD
Yes 113/228 (49.5%) 89/208 (42.8%) 1.31 (0.88, 1.95)
No 115/228 (50.4%) 119/208 (57.2%) 0.16
Medications
Immunosuppression
Yes 73/228 (32.0%) 82/208 (39.4%) 0.72 (0.48, 1.09)
No 155/228 (68.0%) 126/208 (60.6%) 0.11
Azole antifungals
Yes 24/228 (10.5%) 29/208 (13.9%) 0.73 (0.39, 1.34)
No 204/228 (89.5%) 179/208 (86.1%) 0.27
Routine use of sun protection
Yes 183/223 (82.1%) 147/203 (72.4%) 1.74 (1.07, 2.84) 1.89 (1.06, 3.37)
No 40/223 (17.9%) 56/203 (27.6%) 0.02 P = 0.03
DASS 21 score (median, IQR) 18 (8, 38) 20 (10,42) P = 0.2
Depression subscale 4 (0,12) 6 (2,14) P = 0.03
Anxiety subscale 4 (2,10) 4 (2,12) P = 0.53
Stress subscale 8 (2,16) 8 (4,16) P = 0.69
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Skin check 
N = 228
No skin check 
N = 208
OR (95% CI) Adjusted OR(95% CI)1 
P- value
FACT- BMT score (median, IQR) 112 (96, 125) 106 (88,119) P = 0.01
Physical well- being subscale 24 (20, 27) 24 (19,26) P = 0.09
Social well- being subscale 22 (17,25) 20 (15, 24) P = 0.11
Emotional well- being subscale 17 (15, 19) 16 (14,19) P = 0.03
Functional well- being subscale 21 (16,24) 19 (14,24) P = 0.08
BMT well- being subscale 29 (25,33) 27 (23,32) P = 0.007
LEE GVHD score (Median, IQR) 21 (9,32) 19 (10, 29) P = 0.51
Global severity GVHD symptoms (%)
None 23 (16.1%) 16 (13.3%) P = 0.64
Mild 65 (45.5%) 64 (53.3%)
Moderate 39 (27.3%) 29 (24.2%)
Severe 16 (11.2%) 11 (9.2%)
Fear of cancer recurrence (median, IQR) 13 (10,16) 14 (11, 17) P = 0.22
Post transplant growth inventory score 57 (37, 70) 60 (44,70) P = 0.42
AUD, Australian Dollars; IRQ, interquartile ranges; PTGI, The Post Traumatic Growth Inventory.
1Variables included in multivariable logistic regression model to adjust for confounding: age, education, income and marital status, time from trans-
plant (<2 years compared to later), underlying diagnosis (acute leukemia compared to other), conditioning regimen (myeloablative compared to re-
duced intensity), and “sun smart” practices.
Bold text indicates statistically significant figures.
Appendix A1. Continued.
Appendix A2. Demographic, social determinants, transplant factors, and instrument measures (QoL, psychological morbidity, GVHD, FoCR, PTGI), 
and their associations with having bowel cancer screening.
Bowel Ca screen No Bowel Ca Screen OR (95% CI) Adjusted OR (95% CI)
N = 140 N = 292 P- value P- value1
Gender
Male 79/140 (56.4%) 168/292(57.5%) 0.95(0.62, 1.47)
Female 61/140 (43.6%) 124/292 (42.5%) 0.83
Age (Median, IQR) 59(53, 64) 50(40, 60) 1.06(1.03, 1.08) 1.06 (1.03,1.08)
<0.0001 P < 0.0001
Residence
City/inner regional 128/137(93.4%) 262/285(91.9%) 1.25(0.54, 3.15)
Outer regional/remote 9/137(6.6%) 23/285(8.1%) 0.69
Education
Some/completed University 50/105(47.6%) 101/222(45.5%) 1.09(0.66,.78)
Trade/some or complete secondary school 55/105(52.4%) 121/222(54.5%) 0.72
Household income (AUD)
Low income $20,000–$39,999 56/136(41.2%) 95/280(33.9%) 1.36(0.87, 2.12)
Middle/High income ≥ $40,000 80/136 (58.8%) 185/280(66.1%) 0.15
Marital status
Married/Defacto 116/136(85.3%) 222/289(76.8%) 1.75(0.99, 3.20) 1.14(0.63, 2.07)
Single/Divorced/separated 20/136(14.7%) 67/289(23.2%) 0.04 P = 0.65
Years since transplant
<2 years 13/140(9.3%) 44/292(15.1%) 0.58(0.27, 1.14) 0.61(0.30, 1.21)
≥2 years 127/140(90.7%) 248/292(84.9%) 0.13 P = 0.16
Underlying diagnosis
Acute Leukemia 60/135 (44.4%) 158/279(56.6%) 0.61(0.39, 0.95) 0.75(0.48, 1.19)
Other 75/135(55.6%) 121/279 (43.4%) 0.02 P = 0.23
Donor type
Matched (sibling/unrelated) 126/138(91.3%) 274/292(93.8%) 0.69(0.30, 1.62)
Mismatched (haploidentical, unrelated) 12/138 18/292(6.2%) 0.42
Conditioning
Myeloablative 57/138(41.3%) 155/292(53.1%) 0.62(0.40, 0.95) 1.20(0.72,2.00)
Reduced Intensity 81/138(58.7%) 137/292(46.9%) 0.02 P = 0.49
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Bowel Ca screen No Bowel Ca Screen OR (95% CI) Adjusted OR (95% CI)
N = 140 N = 292 P- value P- value1
GVHD
Yes 98/135(72.6%) 196/290(67.6%) 1.27(0.79, 2.06)
No 37/135(27.4%) 94/290(32.4%) 0.3
Self- reported GUT GVHD
Yes 26/140 (18.6%) 34/292 (11.6%)  1.73(0.95, 3.12) 1.66(0.90, 3.05
No 114/140(81.4%) 258/292(88.4%) 0.05 P = 0.10
Medications
Immunosuppression
Yes 49/140(35.0%) 103/292 (35.3%) 0.98(0.63, 1.54)
No 91/140(65.0%) 189/292(64.7%) 0.95
DASS 21 score (Median, IQR) 19(10,38) 20(9,40) P = 0.97
Depression subscale 4(2,14) 6(2,14) P = 0.79
Anxiety subscale 4(2,8) 6(2,10) P = 0.43
Stress subscale 10(4,18) 8(2,16) P = 0.43
FACT- BMT score(Median, IQR) 112(93, 122) 108(92,122) P = 0.39
Physical well- being subscale 24(20, 26) 24(19,26) P = 0.46
Social well- being subscale 22(17,25) 21(16, 24) P = 0.14
Emotional well- being subscale 17(14, 19) 17(14,19) P = 0.79
Functional well- being subscale 20(15,24) 20(15,25) P = 0.83
BMT subscale 29(24,33) 28(23,32) P = 0.51
LEE GVHD score (median, IQR) 16(8, 28) 21(10,32) P = 0.06
Global severity GVHD symptoms (%)
Mild 15(16.5%) 26 (15.0%) P = 0.76
Moderate 47(51.6%) 81 (46.8%)
Severe 20(22.0%) 48 (27.7%)
Very Severe 9(9.9%) 18(10.4%)
Fear of cancer recurrence (Median, IQR) 13(10, 15) 14(10,17) P = 0.3
Post transplant growth inventory Score 58(42, 70) 58(38, 71) P = 0.81
AUD, Australian Dollars; IRQ, interquartile ranges; PTGI, The Post Traumatic Growth Inventory
1Variables included in multivariable logistic regression model to adjust for confounding: age, marital status, time from transplant (<2 years compared 
to later), underlying diagnosis (acute leukemia compared to other), conditioning regimen (myeloablative compared to reduced intensity), and gut 
GVHD.
Bold text indicates statistically significant figures.
Appendix A2. Continued.
Appendix A3. Demographic, social determinants, transplant factors, and instrument measures (QoL, psychological morbidity, GVHD, FoCR, PTGI), and 
their associations with cervical cancer screening
Cervical screen N = 118 No cervical 
screen N = 68
OR (95% CI) Adjusted OR (95% CI)1
P- value
Age (Median, IQR) 50(42, 58) 56 (42, 63)  0.04 0.97(0.94, 1.00)
P = 0.09
Residence
City/inner regional 109/117(93.2%) 58/65(89.2%) 1.64(0.48, 5.47)
Outer regional/remote 8/117(6.8%) 7/65(10.8%) 0.4
Education
Some/completed University 41/93 (44.1%) 19/54 (35.2%) 1.45(0.69, 3.09)
Trade/some or complete secondary school 52/93(55.9%) 35/54 (64.8%) 0.3
Household income (AUD)
Low income $20,000–$39,999 45/113 (39.8%) 25/66(37.9%) 1.81(0.86, 3.93) 1.13(0.58,2.19)
Middle/High income ≥ $40,000 68/113(60.2%) 41/66(62.1%) 0.09 P = 0.71
Marital status
Married/Defacto 92/113 (81.4%) 52/87 (77.6%) 1.26(0.55, 2.82)
Single/Divorced/separated 21/113 (18.6%) 15/67(22.4%) 0.54
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Cervical screen N = 118 No cervical 
screen N = 68
OR (95% CI) Adjusted OR (95% CI)1
P- value
Years since transplant
<2 years 8/118 (6.8%) 14/68 (20.6%) 0.28(0.09, 0.77) 0.30(0.11, 0.85)
≥2 years 110/118 (93.2%) 54/68(79.4%) 0.008 P = 0.02
Underlying diagnosis
Acute Leukemia 71/111(64.0%) 39/66(59.1%) 1.22(0.62, 2.40)
Other 40/111(36.0%) 27/66(40.9%) 0.52
Donor type
Matched (sibling/unrelated) 108/118(91.5%) 64/68(94.1%) 0.67(0.15, 2.47)
Mismatched (haploidentical, unrelated) 10/118(8.5%) 4/68(5.9%) 0.58
Conditioning
Myeloablative 70/118(59.3%) 33/68(48.5%) 1.55(0.81, 2.95) 0.98(0.47, 2.03)
Reduced Intensity 48/118(40.7%) 35/68(51.5%) 0.15 P = 0.97
GVHD
Yes 78/117(66.7%) 44/66(66.7%) 1.0(0.50, 1.98)
No 39/117(33.3%) 22/66(33.3%) 1
Self- reported vaginal GVHD
Yes 25/118(21.2%) 16/68(25.5%) 0.87(0.40, 1.92)
No 93/118(78.8%) 52/68(76.5%) 0.71
Medications
Immunosuppression
Yes 25/118 (21.2%) 21/68(30.9%) 0.60(0.30, 1.26) 0.78(0.38, 1.61)
No 93/118 (78.8%) 47/68(69.1%) 0.14 P = 0.50
DASS 21 score (Median, IQR) 18(8,34) 20(10,40) P = 0.21
Depression subscale 4(1,9) 4(0,12) P = 0.28
Anxiety subscale 4(1,8) 6(2, 10) P = 0.06
Stress subscale 8(2,14) 10(4,16) P = 0.63
FACT- BMT score (Median, IQR) 111(99, 123) 104(91, 119) P = 0.02
Physical well- being subscale 25(22,27) 24(18,26) P = 0.12
Social well- being subscale 22(17,26) 21(18,26) P = 0.89
Emotional well- being subscale 17(15,19) 16(14, 18) P = 0.054
Functional well- being subscale 21(18,26) 19(16,23) P = 0.008
BMT well- being subscale 28(25,32) 27(22, 32) P = 0.07
LEE GVHD score (Median, IQR) 14 (8, 28) 19(9, 28) P = 0.25
Global severity GVHD symptoms (%)
Mild 12(16.0%) 6(17.1%)
Moderate 41(54.5%) 15(42.9%) P = 0.68
Severe 19(25.3%) 12(34.3%)
Very Severe 3(4.0%) 2(5.7%)
Fear of cancer Recurrence (Median, IQR) 12(9,15) 15(10,18) P = 0.003
Post transplant Growth Inventory Score 59(44,71) 68(49, 82) P = 0.1
PTGI, The Post Traumatic Growth Inventory.
1Potential confounders included in multivariable logistic regression: age, income status (low compared to middle/high income), early post transplant 
(within 2 years), conditioning regimen (myeloablative compared to reduced intensity), and taking immunosuppression (tacrolimus, cyclosporine, my-
cophenolate, or prednisolone). IRQ, interquartile ranges.
Bold text indicates statistically significant figures.
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Mammogram N = 98 No Mammogram N = 86 OR (95% CI) P- value Adjusted1 OR (95% 
CI) P-value
Age (median, IQR) 57(50, 63) 43(32, 54) 1.09 (1.06, 1.13) 1.12(1.08, 1.17)
<0.0001 P < 0.0001
Residence
City/inner regional 92/96 (95.8%) 73/84(86.9%) 3.46(0.97, 15.4) 4.81(1.16, 19.9)
Outer regional/remote 4/96 (4.2%) 11/84 (13.1%) 0.06 P = 0.03
Education
Some/completed University 35/83(42.2%) 23/63(36.5%) 1.27(0.61, 2.63)
Trade/some or complete secondary 
school
48/83(57.8%) 40/63(63.5%) 0.49
Household income (AUD)
Low income $20,000–$39,999 39/96 (40.6%) 30/82(36.6%) 1.18(0.62, 2.28)
Middle/High income ≥ $40,000 57/96 (59.4%) 52/82(63.4%) 0.58
Marital status
Married/Defacto 80/94(85.1%) 62/84(73.8%) 2.03(0.90, 4.64) 1.13(0.42, 3.07)
Single/divorced/separated 62/94 (73.8%) 22/84(26.2%) 0.06 P = 0.63
Years since transplant
<2 years 6/98 (6.1%) 14/86 (16.3%) 0.33(0.10, 0.99) 0.31(0.09, 1.05)
≥2 years 92/98 (93.9%) 72/86(83.7%) 0.03 P = 0.06
Underlying diagnosis
Acute Leukemia 57/96(59.4%) 53/81(65.4%) 0.77(0.40, 1.50)
Other 39/96 (40.6%) 28/81(34.6%) 0.41
Donor type
Matched (sibling/unrelated) 90/98(91.8%) 79/86 (92.9%) 0.99(0.29, 3.30)
Mismatched (haploidentical, unrelated) 8/98(8.2%) 7/86(7.1%) 1
Conditioning
Myeloablative 49/98(50%) 56/86(65.1%) 0.53(0.28, 1.01) 0.98(0.41, 2.37)
Reduced intensity 49/98(50%) 30/86(34.9%) 0.04 P = 0.98
Total body irradiation
Yes 34/98 (34.7%) 28/86(32.6%) 1.1 (0.57, 2.13) 2.35(0.99, 5.58)
No 64/98(65.3% 58/86(67.4%) 0.76 P = 0.052
GVHD
Yes 61/96(63.5%) 60/85(70.6%) 0.73(0.37, 1.42)
No 35/96(36.5%) 25/85(29.4%) 0.31
Medications
Immunosuppression
Yes 22/98 (22.5%) 24/86(27.9%) 0.75(0.36, 1.54)
No 76/98(77.5%) 62/86(72.1%) 0.39
DASS 21 score (median, IQR) 19(8,30) 20(8,40) P = 0.36
Depression subscale 4(0,8) 6(2,12) P = 0.04
Anxiety subscale 4(2,8) 4(2,10) P = 0.3
Stress subscale 10(3,14) 8(2,16) P = 0.99
FACT- BMT score (Median, IQR) 114(101, 126) 107(93, 119) P = 0.02
Physical well- being subscale 25(21,27) 24(20,27) P = 0.24
Social well- being subscale 22(17,26) 20(17,25) P = 0.18
Emotional well- being subscale 18(16,19) 16(13,18) P < 0.001
Functional well- being subscale 21(17,26) 20(16, 23) P = 0.15
BMT well- being subscale 29(25,32) 27(23,31) P = 0.049
Appendix A4. Demographic, social determinants, transplant factors, and instrument measures (QoL, psychological morbidity, GVHD, FoCR, and 
PTGI), and their associations with breast cancer screening.
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Mammogram N = 98 No Mammogram N = 86 OR (95% CI) P- value Adjusted1 OR (95% 
CI) P-value
LEE GVHD score (Median, IQR) 12(7, 24) 19(11, 29) P = 0.02
Global severity GVHD symptoms (%)
Mild 12(16.0%) 6 (17.1%) P = 0.68
Moderate 41 (54.7%) 15 (42.9%)
Severe 19 (25.3%) 12 (34.3%)
Very Severe 3(4.0%) 2(5.7%)
Fear of cancer recurrence (Median, IQR) 13(9, 15) 14(9, 17) P = 0.48
Post transplant growth inventory score 61(51, 75) 59(42, 72) P = 0.26
AUD, Australian Dollars; BMT, Bone marrow transplantation; IRQ, interquartile ranges; PTGI, The Post Traumatic Growth Inventory
1Potential confounders included in multivariable logistic regression: age, residential status, marital status, early post transplant (within 2 years), con-
ditioning regimen (myeloablative compared to reduced intensity), and whether total body irradiation was used (Yes, No).
Bold text indicates statistically significant figures.
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